A truck driver in his 50s had a slow stream and a sense that he was not emptying his bladder. Those symptoms were interfering with his ability to do his job. He wanted relief, and he wanted to avoid the risks of transurethral resection of the prostate (TURP) or another urologic procedure. He underwent prostate artery embolization, or PAE.

At about one month, his urinary symptoms had essentially resolved, and the treating physician stopped his BPH medications. By the physician’s recollection, his International Prostate Symptom Score, or IPSS, fell from about 16–17 to 3–4. There was no later visit with the treating physician.

This was a good early result for the patient. Symptoms and medication use improved at one month. The available follow-up gives no five-year outcome, no measured change in urine flow and no measurement of the urine left in his bladder. Technical completion and an early response are the start of assessing the outcome.

Protective coils were placed during his PAE to control where the embolic particles could travel. The arterial anatomy brief shows the connections such coils close.

Figure 1. Coils used for non-target protection during PAE. The image illustrates the protective maneuver; individual protected branches are not labeled.

What follow-up has to measure

Follow-up starts with the problem that brought the patient in. A symptom score is useful because it asks the same questions before and after treatment. The IPSS covers seven urinary symptoms, with a total from 0 to 35. The total tracks change, but the individual symptoms and their effect on the day still matter. A bladder diary adds the timing and the volumes that the score does not capture.1

For a truck driver, the same urinary difficulty carries a different burden than it does for a man with a bathroom down the hall. The first consultation and the follow-up both have to include the patient’s work and daily life.

Five things describe the result: symptoms, urine flow, residual urine, medication and catheter dependence.2 They do not always move together. A man can be pleased with his improvement and still have a residual that needs attention. A better flow measurement does not show that his urgency or his nights have become acceptable.

Feeling better and emptying better

The five-year comparison of PAE and TURP shows how symptom scores, urine flow and bladder emptying can improve by different amounts. TURP wins on symptom score, flow and residual urine; PAE holds up in properly selected men. The difference in symptom scores was not statistically significant, and fewer men reached the five-year visit after PAE than after TURP.

So follow-up has to return to the original goal. If a man was retaining urine, the assessment has to address emptying. If he depended on a catheter, a low symptom score cannot stand in for showing that he voids adequately without it. If he came because of disrupted sleep, the nights have to be asked about directly.

Medication

Being able to stop medication matters to patients. The timing depends on the individual response and why the medication was prescribed.

The published figures give the range. In the largest series, 65.5% of men were free of BPH medication one year after PAE.3 In a ten-year series, 31.3% needed prostate medication after PAE.4 For any one patient, the decision depends on his response, the reason each drug was prescribed, and the plan agreed with his other doctors.

The treating team records whether medication was continued or stopped. A score achieved on medication and a score achieved without it are both useful, when the medication status is recorded. Stopping finasteride or dutasteride also changes how the prostate-specific antigen (PSA) is read, as the enlarged prostate page explains.

The man who came with a catheter

For a man in urinary retention, the result is simple to state: is he free of the catheter? In the largest series, 119 of 126 men in retention, 94%, were catheter-free three months after PAE.3 In an international prospective study, 48 of 73 men treated for acute retention, 65.8%, had the catheter removed within three months and remained catheter-free at two years.5

When the benefit never comes, or fades

Durability belongs in the conversation from the first visit, including the possibility of another treatment later. Little or no initial improvement and worsening after a good response are different problems.

The benefit of PAE builds over time. Many men notice improvement within the first month. Around three months is a useful point to assess the fuller response. Not every man reaches his full improvement by day ninety; improvement can continue after that. Assessing the response around three months does not mean waiting when symptoms persist or worsen; those need an earlier assessment. The enlarged prostate page describes the first days and weeks after embolization.

Early failure: little or no improvement. The treating team reassesses whether PAE treated the cause of the symptoms and whether any prostate arterial supply went untreated. If there is a correctable gap, repeat embolization can be considered. If the first embolization was complete, the team does not simply repeat it: the urologist and interventional radiologist reassess together and consider TURP or holmium laser enucleation (HoLEP).

Late recurrence: a good response, then worse. First, the treating team reassesses the recurrent symptoms. The earlier response is evidence that treating the prostate helped. If he had a good response and it came back, repeat PAE is a reasonable offer, and the data support it.

In a study of 108 men who had a repeat PAE, 39 had never responded to the first treatment and 69 had improved in the first six months and then relapsed. It was a single-center retrospective study, with a median follow-up of 18 months. Clinical success after the repeat procedure was 46.2% against 84.1% at one month, 28.2% against 56.7% at one year, and 16.9% against 51.9% at two to three years. Three-quarters of the returning blood supply came from the artery that had been embolized before, and one-quarter from collateral vessels.6 Prior responders do about twice as well as men who never responded.

Imaging helps when the tissue response or the completeness of treatment is uncertain. It is read together with the symptoms and the functional tests. A three-month MRI is not, by itself, an instruction to repeat treatment.

Either way, the patient, his urologist and the interventional radiologist make the decision together.

How long the benefit lasts

In the largest single-center series, 1,075 men had a median gland size of 107 g. Median symptom scores fell from 23 before PAE to 6 at six to twelve months and were 9 at four to five years.3 In a prospective multicenter study of 405 men treated for bothersome symptoms, the mean score fell from 21.8 before PAE to 10.6 at one year and 11.2 at two years.5

In a single-center series of 1,072 men, the estimated rate of another procedure was 3.4% at one year, 21.1% at five years and 58.1% at ten years. Repeat PAE accounted for 2.3%, 9.5% and 23.1% at those intervals, and prostate surgery for 1.1%, 11.6% and 35.0%. In the same series, in which men were seen yearly for up to ten years, symptom relief held up: at the last visit, the symptom score averaged 10.1 points better than before PAE, and the authors describe the relief as durable. Mean follow-up was 4.39 years, so fewer men contribute to the later figures.4 In a second center’s ten-year experience with 317 men, a retrospective series of consecutive patients, early clinical failure occurred in 1.9% and symptoms recurred in 23%.7

Figure 2. Men needing a further procedure after PAE, in the single-center series of 1,072 men. The share who have had another procedure climbs with time: about 3 in 100 by one year, one in five by five years and more than half by ten, split between repeat PAE and prostate surgery. These are Kaplan–Meier estimates with a mean follow-up of 4.39 years, not the fraction of men actually seen at each point, so fewer men contribute to the later bars. Redrawn from the chart in the talk to urologists, with the data of Bilhim and colleagues.4

Put plainly, about one man in five has had another procedure by five years, either repeat PAE or surgery. That is the honest shape of PAE: it works, it is safe, and it is not a TURP.

One man will consider several years of relief worth the chance of another treatment. Another will put more weight on never having a second procedure. The choice is clearer when those numbers are discussed at the beginning, before a good early result makes it tempting to call the treatment permanent.

Conclusion

A good result at one month is a good start. It is not the outcome. Follow-up has to measure what the patient came for: his symptoms, his emptying, his medication, his catheter.

When PAE does not work, the treating team has to find out why before doing anything else. Repeat embolization can be considered when there is a correctable gap. Repeat PAE is a reasonable offer when a man responded well and then relapsed. When the embolization was complete and he never improved, the team does not simply repeat it: his urologist and interventional radiologist reassess together and consider TURP or HoLEP.

References

  1. European Association of Urology. EAU guidelines on the management of non-neurogenic male LUTS: diagnostic evaluation. Uroweb. 2026. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/diagnostic-evaluation
  2. European Association of Urology. EAU guidelines on the management of non-neurogenic male LUTS: follow-up. Uroweb. 2026. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/followup
  3. Bhatia S, Bhatia A, Richardson AJ, et al. Prostatic artery embolization: mid- to long-term outcomes in 1,075 patients. J Vasc Interv Radiol. 2025;36(3):456–466. https://doi.org/10.1016/j.jvir.2024.11.002
  4. Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45(9):1324–1336. https://doi.org/10.1007/s00270-022-03199-8
  5. Sapoval MR, Bhatia S, Déan C, et al. Two-year outcomes of prostatic artery embolization for symptomatic benign prostatic hyperplasia: an international, multicenter, prospective study. Cardiovasc Intervent Radiol. 2024;47(11):1515–1524. https://doi.org/10.1007/s00270-024-03802-0
  6. Costa NV, Torres D, Pisco J, et al. Repeat prostatic artery embolization for patients with benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(8):1272–1280. https://doi.org/10.1016/j.jvir.2020.04.027
  7. Carnevale FC, Moreira AM, de Assis AM, et al. Prostatic artery embolization for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: 10 years’ experience. Radiology. 2020;296(2):444–451. https://doi.org/10.1148/radiol.2020191249